aseptic technique comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Peptide, oligopeptide, polypeptide | Usage varies; polypeptide often implies a longer chain |
| Purity assessment | High-performance liquid chromatography | Often reversed-phase; reported as area percent with method and wavelength stated |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical mass within instrument tolerance |
| Water content (lyophilized) | Karl Fischer titration | Residual moisture can affect stability and weighing accuracy |
| Container compatibility | Low-binding polypropylene | Glass may adsorb some peptides; plastic additives can leach |
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
20,000, 11 December 2007- On 29 October 2007, the SENSEX crossed the 20,000 mark for the first time with a massive 734.5-point gain, but closed below the 20,000 mark. The SENSEX would close above the 20,000 mark for the first time on 11 December 2007. It took 42 days after reaching the 19,000 milestone to close above 20,000 points for the first time. The journey of the last 10,000 points was covered in just 483 sessions, compared to 7,297 sessions taken to touch the 10,000 mark from its base value of 100 points. In the second half of 2007 alone, the SENSEX reached six 1,000-point milestones.
Early European alchemists gave sulfur an alchemical symbol of a triangle atop a cross (🜍). Another type of sulfur mentioned in alchemy, black sulfur (sulfur nigrum), also had its own symbol combining a two-barred cross atop a lemniscate (🜏). This symbol was later used by Anton LaVey as a satanist symbol, the "Leviathan cross", as he associated it with the brimstone of Hell. This has led to some confusion and misconceptions about its original alchemical meaning: in alchemical texts, black sulfur was not a synonym for "brimstone" or an alternative symbol for sulfur as one of the Three Primes, but was instead considered a distinct type of sulfur, listed separately. Black sulfur, also known as grey sulfur (sulfur griseum) or "horse brimstone" (sulfur caballinum), was a grey, impure form of sulfur, usually the dregs of sulfur purification, which was used for medicinal purposes despite often containing arsenic. Iron shavings or hammerscale were sometimes added to it in its manufacture. The "horse" in the name is thought to reference its veterinary use: low quality sulfur, only fit to treat horses. In the 19th century, it was sometimes also sold under the name "sulphur of ivy" (a corruption of sulfur vivum) and used on hops.
By late June, senior counter-terrorism official Richard Clarke and CIA director George Tenet were "convinced that a major series of attacks was about to come", although the CIA believed the attacks would likely occur in Saudi Arabia or Israel. In early July, Clarke put domestic agencies on "full alert", telling them, "Something spectacular is going to happen here, and it's going to happen soon." He asked the FBI and the State Department to alert the embassies and police departments, and the Defense Department to go to "Threat Condition Delta." Clarke later wrote: Somewhere in CIA there was information that two known al-Qaeda terrorists had come into the United States. Somewhere in the FBI, there was information that strange things had been going on at flight schools in the United States. [...] They had specific information about individual terrorists from which one could have deduced what was about to happen. None of that information got to me or the White House.
Sources: en.wikipedia.org
== Factors == Factor XIa and XIIa are two main factors involved in the plasminogen activator. Factor XI (FXI) is a serine protase produced by the liver and circulates in its inactive form. Deficiency in factor XI is known to cause hemophilia C. Factor XIIa is another plasma protein that is involved in the activation of zymogen factor is activated into factor XIa. This activation is important to the coagulation cascade.
==== Construction ==== Although these bridges were assembled using twisted mountain grass, other vegetation, and saplings, they were dependable. These structures were able to both support the weight of traveling people and animals as well as withstand weather conditions over certain amounts of time. Since grass rots away over time, the bridges had to be rebuilt every year.
== Further reading == Castka, Joseph F.; Metcalfe, H. Clark; Davis, Raymond E.; Williams, John E. (2002). Modern Chemistry. Holt, Rinehart and Winston. ISBN 978-0-03-056537-3. Guch, Ian (2003). The Complete Idiot's Guide to Chemistry. Alpha, Penguin Group Inc. ISBN 978-1-59257-101-7. Mascetta, Joseph A. (1998). How to Prepare for the SAT II Chemistry. Barron's. ISBN 978-0-7641-0331-5.
As a hormone, adrenaline acts on nearly all body tissues by binding to adrenergic receptors. Its effects on various tissues depend on the type of tissue and expression of specific forms of adrenergic receptors. For example, high levels of adrenaline cause smooth muscle relaxation in the airways but causes contraction of the smooth muscle that lines most arterioles. Adrenaline is a nonselective agonist of all adrenergic receptors, including the major subtypes α1, α2, β1, β2, and β3. Adrenaline's binding to these receptors triggers a number of metabolic changes. Binding to α-adrenergic receptors inhibits insulin secretion by the pancreas, stimulates glycogenolysis in the liver and muscle, and stimulates glycolysis and inhibits insulin-mediated glycogenesis in muscle. β adrenergic receptor binding triggers glucagon secretion in the pancreas, increased adrenocorticotropic hormone (ACTH) secretion by the pituitary gland, and increased lipolysis by adipose tissue. Together, these effects increase blood glucose and fatty acids, providing substrates for energy production within cells throughout the body. Binding of β adrenergic receptor also increases the production of cyclic AMP. Adrenaline causes liver cells to release glucose into the blood, acting through both alpha and beta-adrenergic receptors to stimulate glycogenolysis. Adrenaline binds to β2 receptors on liver cells, which changes conformation and helps Gs, a heterotrimeric G protein, exchange GDP to GTP. This trimeric G protein dissociates to Gs alpha and Gs beta/gamma subunits.
Sources: en.wikipedia.org
== Selected bibliography == Banday Khalid M, Pasikanti KK, Chan EC, Singla R, Rao KV, Chauhan VS, Nanda RK. (July 2011). "Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects". Anal Chem. 83 (14): 5526–34. doi:10.1021/ac200265g. PMID 21619052.{{cite journal}}: CS1 maint: multiple names: authors list (link) Rao KV, Konar S, Gangadharan J, Vikas V, Sampath S (October 2015). "A pure non-gestational ovarian choriocarcinoma with delayed solitary brain metastases: Case report and review of the literature". J Neurosci Rural Pract. 6 (4): 578–81. doi:10.4103/0976-3147.169869. PMC 4692019. PMID 26752905. Jamwal SV, Mehrotra P, Singh A, Siddiqui Z, Basu A, Rao KV (March 2016). "Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism". Sci. Rep. 6 (23089) 23089. Bibcode:2016NatSR...623089J. doi:10.1038/srep23089. PMC 4793295. PMID 26980157. Ghosh AK1, Reddy BS, Yen YC, Cardenas E, Rao KV, Downs D, Huang X, Tang J, Mesecar AD (May 2016). "Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes". Chem. Sci. 1 (7): 3117–3122. doi:10.1039/C5SC03718B. PMC 4916918. PMID 27347366.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
=== Sexual Dysfunction === SNRIs, similarly to SSRIs, can cause several types of sexual dysfunction, such as erectile dysfunction, decreased libido, sexual anhedonia, and anorgasmia. The two common sexual side effects are diminished interest in sex (libido) and difficulty reaching climax (anorgasmia), which are usually somewhat milder with SNRIs compared to SSRIs. To manage sexual dysfunction, studies have shown that switching to or augmenting with bupropion or adding a PDE5 Inhibitor have decreased symptoms of sexual dysfunction. Studies have shown that PDE5 Inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra), have sometimes been helpful to decrease the sexual dysfunction, including erectile dysfunction, although they have been shown to be more effective in men than women.
Susineridine (INNTooltip International Nonproprietary Name; developmental code name YZJ-4729) is an atypical μ-opioid receptor (MOR) agonist and opioid analgesic which is under development for the treatment of postoperative pain. It is given intravenously. The drug acts as a selective biased partial agonist of the MOR, with functional selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its mechanism of action and pharmacological activity are said to be similar to those of oliceridine. However, in-vitro findings suggest that susineridine may have a greater degree of G protein bias than oliceridine. The drug produces analgesic effects in multiple animal models of pain and produces less respiratory depression than morphine or oliceridine. The pharmacokinetics of susineridine in humans have been studied. Susineridine was patented and first described in the scientific literature in 2023. It is under development by Shanghai Haiyan Pharmaceutical Technology in China. As of May 2025, the drug is in phase 3 clinical trials for postoperative pain.
Various medications are approved for treating obesity with varying rates of weight loss between 3-21%, but weight regain is very common after discontinuation. Medications are recommended to be used only in combination with lifestyle changes. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year.
Cl2C=CHCl + KH → ClC≡CCl + KCl + H2 A trace of methanol is required. It has also been generated (and used in situ) using lithium diisopropylamide under anhydrous conditions as well as potassium hydroxide.
Sources: en.wikipedia.org
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.
Vortexing creates rapid air-liquid interfaces that can cause foaming and promote aggregation. Gentle inversion or slow swirling usually dissolves the peptide with less physical stress. Some sequences tolerate vortexing, but minimizing shear is a general precaution.
A certificate of analysis usually reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes water content or counterion. It may also list lot number, storage recommendations, and handling notes. Exact content varies by supplier and product type.
Removing water reduces hydrolytic and some oxidative degradation. Powder forms are generally more stable for long-term storage than solutions. Stability still depends on peptide sequence, residual moisture, and container conditions.